Statement by MassBio President & CEO Robert K. Coughlin on House Budget – Amendment 1057

Apr 24, 2019

“We thank the House for listening to constructive input and taking the time to amend this major policy change to limit its negative consequences. The biotech industry came to the table in good faith and proposed a significant compromise – one we believed kept the original proposal’s intent of restraining costs in MassHealth. Although the House’s amendment fixes many of the major issues, the underlying language proposed by the Governor is still seriously problematic. As the Senate considers their budget, we urge them to take a similarly thoughtful approach to radically reforming MassHealth, which could have long-lasting consequences for patients and our world-leading life sciences cluster.”

– Robert K. Coughlin, President and CEO of MassBio

See all MassBio News